Thus, CXCR2 is identified as a novel target for therapies aiming to inhibit MDSC recruitment and provides a rationale for combining immune checkpoint inhibitors with agents designed to prevent MDSC-mediated immune suppression in cancer therapy (49, 54). This evidence concerns the gene CXCR2 and cancer.